Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

President’s Perspective: Will the Physician Payment Sunshine Act Shed Light on Conflicts of Interest?

Audrey B. Uknis, MD  |  Issue: July 2013  |  July 1, 2013

Will Sunshine Shed Light on Conflicts of Interest?


By now, you’ve heard the Physician Payment Sunshine Act (PPSA) passed on February 1 of this year. The PPSA goes into effect August 1. As this date fast approaches, I have questions about what this will mean for us.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As physicians, we are duty bound to remain free from conflict of interest that may influence our patient care decisions. There is no question that a conflict of interest may serve to undermine the trust that is essential to the therapeutic doctor–patient relationship. The critical issue on which we should focus is that transparency should help to maintain this essential trust. While the PPSA is a well-intentioned attempt to enhance transparency in physician relationships with manufacturers of medications, devices, and medical supplies, it may require a “user’s manual” for interpretation. It is also true that relationships between physicians and manufacturers are often helpful in advancing the science of discovery and facilitating the lifesaving and quality of life–enhancing changes to our medical practices that we have seen in the past two decades.

Only time will tell if the data that manufacturers submit to the Centers for Medicare and Medicaid Services (CMS) as of August 1 will be meaningful to the general public and if the PPSA is beneficial to the doctor–patient relationship. In the meantime, this is what you should know about complying with the PPSA.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

PPSA, Physicians, and Industry

According to CMS, the PPSA is designed to promote transparency in the financial relationships between physicians and industry. Pharmaceutical and device manufacturers must begin tracking payments of gifts of $10 or more to “covered recipients,” as well as reporting covered recipients’ ownership or investments in their companies.

Who Is a Covered Recipient?

The law states that covered recipients include all physicians and teaching hospitals. This includes physicians who do not treat patients, such as medical researchers and physician administrators. It does not include other healthcare professionals such as nurses, nurse practitioners, physician assistants, or pharmacists.

What Will Be Reported?

Any payments or transfers of value from an applicable manufacturer must be reported to CMS. Applicable manufacturers include pharmaceutical and medical device companies. Both direct and indirect payments or transfers of value must be reported.

Payments and transfer of value include items from the list below that exceed $10 in value.

  • Consulting fees
  • Compensation for services other than consulting
  • Honoraria
  • Gifts
  • Entertainment
  • Food
  • Travel (including the specified destinations)
  • Education
  • Research
  • Charitable contributions
  • Royalties or licenses
  • Current or prospective ownership or investment interests

There are some exceptions to this list that include, but are not limited to:

Page: 1 2 3 | Single Page
Share: 

Filed under:Legislation & AdvocacyPresident's Perspective Tagged with:Legislationphysician paymentRegulationrheumatologistSunshine Act

Related Articles

    What Rheumatologists Need to Know About the Physician Payment Sunshine Act

    July 1, 2013

    The federal act mandates transparency within physician–industry relationship

    What the Physician Payment Sunshine Act & Open Payments Database Mean in Practice

    January 1, 2015

    Revised CMS policy on payments, transfers of value to physicians incorporates exemption for continuing medical education

    Working With Your National Provider Number

    May 1, 2008

    Beginning May 23, 2008, all practicing physicians who treat Medicare patients must start billing with a working national provider identifier (NPI). Physician and non-physician providers can make any corrections or changes pertaining to their NPIs by contacting the National Plan and Provider Enumeration System (NPPES)…

    Extended Warranties for Medical Equipment

    September 5, 2012

    The art of purchasing a piece of medical equipment requires the perfect combination of medical, financial, business, and legal expertise.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences